Market Research Reports and Industry Reports

DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable!

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Dainippon Sumitomo (DSP) is one of those Japanese pharma companies which has changed its orbit by successful US launch of Latuda (Lurasidone, dopamine-2, serotonin-2 and serotonin-7 receptors agonist schizophrenia/bipolar disorder) in the last two years. But DSPs expectation to generate $650m by FY2017 from its lead compound BBI-608 from mCRC is way unachievable. Pipeline Cancer Stem Cell Inhibitors- from OncoMed/Celgene (OMP-21M18, OMP-52M51) And Bionomics (BNC-101) also need a close watch. On M & A front (Table 11), DSPs R & D collaboration with Edison pharma for EP-743 to target mitochondrial disease, with Healios for iPS cell technology demonstrates its interest for developing first in class drug to target niche market, but they do not fill the gap which it needs to fulfill its FY2017 MTP targets. Due to that, no possibility should be ruled out for DSP to do some M & A for late stage compound in oncology space or in CNS/Respiratory space. BBI-608 Optimism Is Too High Lead Indication -mCRC Opportunity, Pipeline CSC Inhibitors- From OncoMed/Celgene (OMP-21M18, OMP-52M51) And Bionomics (BNC-101) Need A Close Watch- LATUDA: US Blockbuster potential is unavoidable from genericized schizophrenia/bipolar disorder market, while opportunities in bipolar maintenance, MDD with mixed features and IM Depo formulation will be limited due to APTIOM AND OTHER PIPELINE CANDIDATES.
Maraghy
- Table 2 : COMPETITIVE LANDSCAPE- METASTATIC COLORECTAL CANCER
- Tabl 3 : EARLY STAGE DATA COMPARISON OF CANCER STEM CELL INHIBITORS TARGETING COLON CANCER
- Table 4 : PIPELINE OF DRUGS TARGETING CANCER STEM CELL
- Table 5 : PIPELINE OF BOSTON BIOMEDICAL- Table 6 : PSYCHIATRISTS SEE HIGH UNMET NEED
- Table 7 : PEARL 3 vs. SEROQUEL: OVERALL A GOOD RISK/BENEFIT RATIO
- Table 8 : LATUDA SWOT ANALYSIS
- Table 9 : PEARL 3 EXTENSION STUDY DATA- NON INFERIOR TO SEROQUEL XR
- Table 10: DAINIPPON SUMITOMO-KEY PIPELINE CANDIDATES
- Table 11 : DEALS DONE BY DAINIPPON IN 2013
- Key Milestones Table of Dainippon Sumitomo

List Of Tables

Chart 1: ATYPICAL ANTI-PSYCHOTICS MARKET
chart 2: Dainippon Sumitomo Pharma
PRESENCE OF STEM CELL IN COLON TISSUE

List Of Figures

Maraghy
- Table 2 : COMPETITIVE LANDSCAPE- METASTATIC COLORECTAL CANCER
- Tabl 3 : EARLY STAGE DATA COMPARISON OF CANCER STEM CELL INHIBITORS TARGETING COLON CANCER
- Table 4 : PIPELINE OF DRUGS TARGETING CANCER STEM CELL
- Table 5 : PIPELINE OF BOSTON BIOMEDICAL- Table 6 : PSYCHIATRISTS SEE HIGH UNMET NEED
- Table 7 : PEARL 3 vs. SEROQUEL: OVERALL A GOOD RISK/BENEFIT RATIO
- Table 8 : LATUDA SWOT ANALYSIS
- Table 9 : PEARL 3 EXTENSION STUDY DATA- NON INFERIOR TO SEROQUEL XR
- Table 10: DAINIPPON SUMITOMO-KEY PIPELINE CANDIDATES
- Table 11 : DEALS DONE BY DAINIPPON IN 2013
- Key Milestones Table of Dainippon Sumitomo

Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report

Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the companys structure, operation, SWOT analysis,

USD 175View Report

Sumitomo Dainippon Pharma Co., Ltd. (4506) - Financial and Strategic SWOT Analysis Review

Sumitomo Dainippon Pharma Co., Ltd. (4506) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been

USD 125View Report

DAINIPPON SUMITOMO PHARMA - Expectation From BBI-608 To Achieve FY2017 MTP Target Looks Unachievable!

Dainippon Sumitomo (DSP) is one of those Japanese pharma companies which has changed its orbit by successful US launch of Latuda (Lurasidone, dopamine-2, serotonin-2 and serotonin-7 receptors agonist schizophrenia/bipolar disorder)

USD 500View Report

Dainippon Sumitomo Partnering Deals and Alliances 2010 to 2016

This report provides all the information you require to better understand Dainippon Sumitomo and its partnering interests and activities since 2010.One of the key aspects of partnering is finding those

USD  1495View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 500
  • Site Licence    $ 1000
  • Enterprisewide Licence    $ 1500
$ 500

Reports Details

Published Date : Jan 2013
No. of Pages :14
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment